Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Conditions
Interventions
Upadacitinib
Placebo
Locations
285
United States
Cahaba Dermatology & Skin Health Center /ID# 254876
Birmingham, Alabama, United States
Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564
Fountain Hills, Arizona, United States
Medical Dermatology Specialists /ID# 254226
Phoenix, Arizona, United States
Mayo Clinic - Scottsdale /ID# 254388
Scottsdale, Arizona, United States
Banner University Medicine Dermatology /ID# 255853
Tucson, Arizona, United States
Clinical Trials Institute - Northwest Arkansas /ID# 254924
Fayetteville, Arkansas, United States
Start Date
June 21, 2023
Primary Completion Date
March 1, 2028
Completion Date
March 1, 2028
Last Updated
March 4, 2026
NCT06958211
NCT06921850
NCT06993233
NCT06888193
NCT07316192
NCT06768671
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions